Request Demo
Recent blog posts
Latest Hotspot
8 min read
JPRN-jRCT2071260044 Elacestrant hydrochloride ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
JPRN-jRCT2071260044 clinical trial report covering Elacestrant hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
ChiCTR2600126789 Bevacizumab Recurrent Glioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
ChiCTR2600126789 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07651007 CN122127318 Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07651007 clinical trial report covering CN122127318, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126829 Sacituzumab tirumotecan Locally Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
ChiCTR2600126829 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space
Latest Hotspot
8 min read
NCT07652073 DAT-2645 HRD-positive Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07652073 clinical trial report covering DAT-2645, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07649980 Pucotenlimab Advanced biliary tract cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07649980 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126786 Becotatug vedotin Transitional Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
ChiCTR2600126786 clinical trial report covering Becotatug vedotin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07650240 Prednisone Castration-sensitive prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07650240 clinical trial report covering Prednisone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07649421 Darolutamide Hormone-dependent prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07649421 clinical trial report covering Darolutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07649473 Iparomlimab/Tuvonralimab Liver metastases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07649473 clinical trial report covering Iparomlimab/Tuvonralimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07649291 Duloxetine Hydrochloride Depressive Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07649291 clinical trial report covering Duloxetine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07650656 Indocyanine Green High Grade Sarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07650656 clinical trial report covering Indocyanine Green, Phase 2, endpoints, sponsor, geography, readout timing and development white space.